Nimbus Therapeutics

JPM 24: How Takeda beat 'almost every biopharmaceutical company' to win Nimbus’ TYK2 med
Fierce Biotech
Thu, 01/11/24 - 11:17 am
Takeda
TAK-279
Nimbus Therapeutics
JPMHC 2024
Fresh off $4B deal, Nimbus gears up for ‘third chapter’ with new fundraise
BioPharma Dive
Wed, 09/6/23 - 10:08 am
Nimbus Therapeutics
Takeda
funding
cancer
Nimbus hopes to strike thrice
EP Vantage
Tue, 02/7/23 - 11:08 am
Nimbus Therapeutics
NASH
firsocostat
Takeda focuses on ‘diverse’ pipeline prospects on heels of two acquisitions
Endpoints
Mon, 02/6/23 - 10:55 am
Takeda
Nimbus Therapeutics
Hutchmed
colorectal cancer
psoriasis
fruquintinib
10 clinical trials to watch in the first half of 2023
BioPharma Dive
Tue, 01/3/23 - 10:57 am
clinical trials
Alzheimer's disease
obesity
Huntington's disease
M&A
AstraZeneca
Daiichi Sankyo
Nimbus Therapeutics
Takeda
Eli Lilly
Sanofi
Regeneron
Moderna Therapeutics
Gilead Sciences
Pfizer
Roivant
Alnylam
uniQure
Takeda wagers up to $6B on Nimbus’ TYK2 drug
BioPharma Dive
Tue, 12/13/22 - 10:43 am
Takeda
Nimbus Therapeutics
autoimmune diseases
NDI-034858
Nimbus on cloud 9 as psoriasis data support taking rival to Bristol Myers' Sotyktu into phase 3
Fierce Biotech
Wed, 11/30/22 - 10:38 am
Nimbus Therapeutics
Sotyktu
Bristol Myers Squibb
clinical trials
NDI-034858
Nimbus raises $125M to advance rival to Bristol Myers’ new psoriasis drug
BioPharma Dive
Mon, 09/12/22 - 11:39 pm
Nimbus Therapeutics
psoriasis
Bristol Myers Squibb
Sotyktu
Next-gen psoriasis drug rivalry between Bristol Myers and Nimbus spills into a legal battle
Endpoints
Tue, 08/17/21 - 10:56 pm
Bristol Myers Squibb
Celgene
Nimbus Therapeutics
psoriasis
deucravacitinib
Celgene bags option on Nimbus' anticancer HPK1 inhibitor
Fierce Biotech
Tue, 07/9/19 - 08:45 am
Celgene
Nimbus Therapeutics
HPK1 inhibitors